NASDAQ:GLUE Monte Rosa Therapeutics (GLUE) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free GLUE Stock Alerts $7.05 +0.01 (+0.14%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$6.80▼$7.1550-Day Range$4.26▼$8.4652-Week Range$2.44▼$8.84Volume99,848 shsAverage Volume153,229 shsMarket Capitalization$353.59 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Monte Rosa Therapeutics alerts: Email Address Monte Rosa Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside56.0% Upside$11.00 Price TargetShort InterestBearish5.79% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.25) to ($2.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.66 out of 5 starsMedical Sector726th out of 938 stocksBiological Products, Except Diagnostic Industry117th out of 149 stocks 3.3 Analyst's Opinion Consensus RatingMonte Rosa Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Monte Rosa Therapeutics has a forecasted upside of 56.0% from its current price of $7.05.Amount of Analyst CoverageMonte Rosa Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.79% of the float of Monte Rosa Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonte Rosa Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous monthShort interest in Monte Rosa Therapeutics has recently decreased by 0.54%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMonte Rosa Therapeutics does not currently pay a dividend.Dividend GrowthMonte Rosa Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GLUE. Previous Next 3.0 News and Social Media Coverage News SentimentMonte Rosa Therapeutics has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Monte Rosa Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for GLUE on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows6 people have added Monte Rosa Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Monte Rosa Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.30% of the stock of Monte Rosa Therapeutics is held by insiders.Percentage Held by Institutions79.96% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Monte Rosa Therapeutics are expected to grow in the coming year, from ($2.25) to ($2.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Monte Rosa Therapeutics is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Monte Rosa Therapeutics is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMonte Rosa Therapeutics has a P/B Ratio of 1.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About Monte Rosa Therapeutics Stock (NASDAQ:GLUE)Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops an orally bioavailable molecular glue degrader for GSPT1, a a translation termination factor for the treatment of Myc-driven cancers. It also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as gout and Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and a therapeutically-relevant protein in hemoglobinopathies. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.Read More GLUE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLUE Stock News HeadlinesMarch 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Moderna (MRNA) and Monte Rosa Therapeutics (GLUE)March 19, 2024 | finance.yahoo.comWall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should KnowMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 16, 2024 | finance.yahoo.comMonte Rosa Therapeutics Inc (GLUE) Reports Full Year and Q4 2023 Financial ResultsMarch 15, 2024 | finance.yahoo.comIs Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?March 14, 2024 | markets.businessinsider.comPromising Clinical Progress and Strategic Milestones Bolster Buy Rating for Monte Rosa TherapeuticsMarch 14, 2024 | investorplace.comGLUE Stock Earnings: Monte Rosa Therapeutics Misses EPS for Q4 2023March 14, 2024 | finanznachrichten.deMonte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 14, 2024 | benzinga.comMonte Rosa Therapeutics: Q4 Earnings InsightsMarch 14, 2024 | globenewswire.comMonte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 11, 2024 | globenewswire.comMonte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway InhibitorMarch 1, 2024 | morningstar.comMonte Rosa Therapeutics Inc GLUEFebruary 24, 2024 | msn.comMonte Rosa Therapeutics (GLUE) Price Target Increased by 5.66% to 16.32February 23, 2024 | benzinga.comMonte Rosa Therapeutics Stock (NASDAQ:GLUE), Analyst Ratings, Price Targets, PredictionsFebruary 15, 2024 | msn.comMonte Rosa draws bullish view at Wedbush on protein degradationFebruary 15, 2024 | msn.comMonte Rosa Therapeutics' AI And Machine Learning Platform Is Adding Significant Value Creation in Cancer Research: AnalystJanuary 16, 2024 | fool.com3 Incredible Growth Stocks That Could Soar in 2024, According to Wall StreetJanuary 8, 2024 | finance.yahoo.comMonte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024January 3, 2024 | finance.yahoo.comMonte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 4, 2023 | benzinga.comMonte Rosa Therapeutics Stock (NASDAQ:GLUE) Earnings Dates and Earning CallsDecember 4, 2023 | benzinga.comMonte Rosa Therapeutics Stock (NASDAQ:GLUE) Dividends: History, Yield and DatesNovember 21, 2023 | finance.yahoo.comMonte Rosa Therapeutics to Present at Piper Sandler Healthcare ConferenceNovember 14, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Celldex (CLDX), Monte Rosa Therapeutics (GLUE) and Solid Biosciences (SLDB)November 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Vertex (VERX) and Monte Rosa Therapeutics (GLUE)November 9, 2023 | benzinga.comMonte Rosa Therapeutics: Q3 Earnings InsightsNovember 9, 2023 | finance.yahoo.comMonte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateSee More Headlines Receive GLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today3/29/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:GLUE CUSIPN/A CIK1826457 Webwww.monterosatx.com Phone617-949-2643FaxN/AEmployees133Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+56.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-135,350,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-65.93% Return on Assets-47.35% Debt Debt-to-Equity RatioN/A Current Ratio5.07 Quick Ratio5.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.58 per share Price / Book1.97Miscellaneous Outstanding Shares50,154,000Free Float47,496,000Market Cap$353.59 million OptionableOptionable Beta1.43 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Markus Warmuth M.D. (Age 52)President, CEO & Director Comp: $901.35kDr. Owen B. Wallace Ph.D. (Age 55)Chief Scientific Officer Comp: $630.68kDr. Filip Janku M.D. (Age 49)Ph.D., Chief Medical Officer Comp: $658.66kMs. Jennifer ChampouxChief People & Operations OfficerDr. Sharon Townson Ph.D. (Age 49)Chief Technology Officer Dr. John C. Castle Ph.D. (Age 52)Chief Data & Information Officer Mr. Andrew FunderburkSenior VP and Head of IR & Strategic FinanceMr. Philip Nickson J.D. (Age 45)Ph.D., General Counsel Mr. Magnus Walter DPHILSenior Vice President of Drug DiscoveryMr. Edmund Dunn (Age 58)Vice President & Corporate Controller More ExecutivesKey CompetitorsSOPHiA GENETICSNASDAQ:SOPHHumacyteNASDAQ:HUMAFennec PharmaceuticalsNASDAQ:FENCAdverum BiotechnologiesNASDAQ:ADVMAura BiosciencesNASDAQ:AURAView All CompetitorsInstitutional OwnershipVanguard Group Inc.Sold 39,960 shares on 3/11/2024Ownership: 3.172%Goldman Sachs Group Inc.Sold 17,032 shares on 3/1/2024Ownership: 0.074%Price T Rowe Associates Inc. MDBought 1,070,360 shares on 2/16/2024Ownership: 9.866%Legal & General Group PlcSold 14,457 shares on 2/15/2024Ownership: 0.040%Citadel Advisors LLCBought 11,000 shares on 2/15/2024Ownership: 0.000%View All Institutional Transactions GLUE Stock Analysis - Frequently Asked Questions Should I buy or sell Monte Rosa Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Monte Rosa Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GLUE shares. View GLUE analyst ratings or view top-rated stocks. What is Monte Rosa Therapeutics' stock price target for 2024? 3 Wall Street analysts have issued 12-month price objectives for Monte Rosa Therapeutics' stock. Their GLUE share price targets range from $11.00 to $11.00. On average, they predict the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 56.0% from the stock's current price. View analysts price targets for GLUE or view top-rated stocks among Wall Street analysts. How have GLUE shares performed in 2024? Monte Rosa Therapeutics' stock was trading at $5.65 at the beginning of the year. Since then, GLUE shares have increased by 24.8% and is now trading at $7.05. View the best growth stocks for 2024 here. When is Monte Rosa Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our GLUE earnings forecast. How were Monte Rosa Therapeutics' earnings last quarter? Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) posted its quarterly earnings results on Thursday, March, 14th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $0.01. What ETF holds Monte Rosa Therapeutics' stock? Range Cancer Therapeutics ETF holds 18,664 shares of GLUE stock, representing 1.26% of its portfolio. When did Monte Rosa Therapeutics IPO? Monte Rosa Therapeutics (GLUE) raised $211 million in an IPO on Thursday, June 24th 2021. The company issued 11,700,000 shares at $17.00-$19.00 per share. Who are Monte Rosa Therapeutics' major shareholders? Monte Rosa Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (9.87%), Price T Rowe Associates Inc. MD (9.87%), Vanguard Group Inc. (3.17%), Vanguard Group Inc. (3.17%), Northern Trust Corp (0.57%) and Charles Schwab Investment Management Inc. (0.49%). Insiders that own company stock include Cormorant Asset Management, Lp and Versant Venture Capital Vi, L. How do I buy shares of Monte Rosa Therapeutics? Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GLUE) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.